![]() ![]() ![]() ![]() Our campaign to inform doctors about the benefits of various tests, such as (indiscernible) primary service of cancer screening, the use of ImmunoCAP for allergy testing, and tests to determine (indiscernible) are improving patient sales and driving growth. Our sales reps' knowledge of new and innovative products is also an invaluable source of information for doctors to improve patient care. We are giving them better tools and training as well as new products to sell. We continued to expand our sales force particularly in high-growth specialty areas. In January 2005, Quest CEO Surya Mohapatra, PhD said (transcript of "Q4 2004 Quest Diagnostics Earnings Conference Call"): is experiencing growth from the HPV DNA Cervical Cancer Screening Test, ImmunoCAP Allergy Test, and Insure Colorectal Cancer Screening Test" (transcript of "Event Brief of Q1 2004 Quest Diagnostics Earnings Conference Call"). In April 2004, the company reported to investors, "The co. In April 2003, Quest's Ken Freeman called the ImmunoCAP partnership with Pharmacia a "national co-marketing initiative" (transcript from "Event Brief of Q1 2003 Quest Diagnostics Earnings Conference Call"). "Together with Pharmacia Diagnostics, we want to help primary care physicians better understand how they can improve patient care through the appropriate use of allergy blood testing." Schwartz, M.D., Vice President and Chief Laboratory Officer of Quest Diagnostics. That's what's happening now with allergy blood testing," said Joyce G. "Quest Diagnostics is well-positioned to inform physicians about the role, value and use of diagnostic markers as they move into mainstream medical practice. In May 2004, Pharmacia and Quest announced a partnership, to educate "primary care physicians about the benefits of Specific IgE blood testing using ImmunoCAP." From a May 18, 2004, press release on PR Newswire: The test was developed by Pharmacia Diagnostics, which announced in March 2001 that "the ImmunoCAP Allergy Blood Test became the first and only allergy test to be accepted as a truly quantitative test by the United States Food and Drug Administration." Īmong the tests Quest Diagnostics offers for primary care physicians is ImmunoCAP (R), a blood test for allergies. Quest Diagnostics also "performs specialized testing for hospitals and laboratories" in countries on every continent, besides Africa. Internationally, the company operates laboratories in the United Kingdom, Mexico, and Puerto Rico supports clinical drug trials in Belgium, France and the UK and carries out research via Nichols Institute Diagnostics outposts in France and Germany. "Today, Quest Diagnostics performs testing for more than 500,000 patients each day, serving approximately half of the physicians and hospitals in the United States." "With $4.7 billion in annual revenues, Quest Diagnostics offers the broadest access to clinical testing services through its national network of 30-plus regional laboratories, approximately 155 rapid response laboratories and almost 2,000 patient service centers," its website states. Quest Diagnostics is a New Jersey-based company offering laboratory tests and services, developing testing equipment and reagents, and providing laboratory services for clinical research trials on new drugs.
0 Comments
Leave a Reply. |